The Value of a Panel of Autoantibodies for Predicting the Activity of Lupus Nephritis at Time of Renal Biopsy

Table 1

Clinical and histological characteristics at renal biopsy of the 107 lupus nephritis patients enrolled in the study who received 111 renal biopsies.

Males/females	13/94
Age at diagnosis of renal biopsy (M ± SD)	36.4 ± 13.9
Duration of SLE years (M ± SD)	5.1 ± 6.5
Serum creatinine mg/dL (M ± SD)	1.07 ± 0.76
Number of patients with serum creatinine >1.2 mg/dL	31 (28%)
Proteinuria g/24 h (M ± SD)	3.4 ± 2.85
Number of patients with nephrotic syndrome	44 (39.6%)
Hemoglobin g/dL	11.53 ± 1.9
Class II (number of patients)/activity index/chronicity index	8 (7.2%)/1.6 ± 3.2/0.4 ± 0.9
Class III (number of patients)/activity index/chronicity index^*	35 (31.5%)/5.3 ± 2.5/1.7 ± 1.74
Class IV (number of patients)/activity index/chronicity index^**	50 (45%)/9.0 ± 3.2/2.1 ± 1.7
Class V (number of patients)/activity index/chronicity index	18 (16.2%)/1.1 ± 2.1/0.7 ± 1.2
Methylprednisolone pulses 0.5–1 g/day for 3 days^***	80 (72%)
Oral prednisone 1 mg/kg/day for 1 month	31 (28%)
Oral cyclophosphamide 1-2 mg/kg/day for 2-3 months	36 (32%)
6 fortnightly cyclophosphamide pulses of of 0.5 g	11 (10%)
6 monthly cyclophosphamide pulses of 1	18 (16%)
Mycophenolate mofetil 2 g/day^$	20 (18%)
Maintenance therapy: mycophenolate mofetil/azathioprine	30/21

M, mean; SD, standard deviation. ^*including 15 patients with class III + V; ^**including 15 patients with class IV + V; ^***(1 patient of class II, 27 of class III, 45 of class IV, and 7 of class V); (14 patients of class III and 22 of class IV); (3 patients of class III, 6 of class IV, and 2 of class V); (2 patients of class II, 5 of class III, 10 of class IV, and 1 of class V), ^$(2 patients of class II, 5 of class III, 8 of class IV, and 5 of class V).